SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced plans to present a poster on IL-11 receptor-blocking as a novel therapeutic approach for lung fibrosis at the upcoming Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado, June 12-16, 2022.
The presentation will describe development of high affinity, high potency IL-11 receptor blocking antibodies selective for mouse and human IL-11Rα. Using these antibodies, the mechanism by which IL-11 drives in vitro fibroblast activation and function was investigated and the efficacy of IL-11 receptor blockade to inhibit fibrosis using human lung tissues and animal models of lung fibrosis was assessed.
Details of the presentation are as follows:
Title: IL-11 Receptor-Blocking as a Novel Therapeutic Approach for Lung Fibrosis
Poster Number: 3017
Session Date and Time: Poster Session 3, June 15, 2022
About Lassen Therapeutics
Lassen Therapeutics develops breakthrough antibodies as potential treatments for fibrosis, rare diseases, and oncology. The company’s lead candidate is LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be safer than and additive to other anti-fibrotic therapeutic approaches. IL-11 is also an important effector of tumor microenvironment organization, playing a key role as a mediator between cancer and stromal cells. For more information, please visit www.lassentherapeutics.com
